Urovant Sciences

$16.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.00 (-0.00%) As of 4:10 PM UTC today

Why Robinhood?

You can buy or sell UROV and other stocks, options, and ETFs commission-free!

About UROV

Urovant Sciences Ltd. Common Stock, also called Urovant Sciences, is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. The listed name for UROV is Urovant Sciences Ltd. Common Stock.

CEO
James A. Robinson
Employees
—
Headquarters
London, Greater London
Founded
2016
Market Cap
529.77M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
81.21K
High Today
$16.22
Low Today
$16.17
Open Price
$16.18
Volume
17.84K
52 Week High
$16.25
52 Week Low
$6.55

UROV Earnings

-$1.59
-$1.34
-$1.10
-$0.85
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
-$1.59 per share
Actual
-$1.46 per share

You May Also Like

LKFN
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure